Poseida Therapeutics Inc. (PSTX): Price and Financial Metrics
PSTX Price/Volume Stats
Current price | $3.19 | 52-week high | $4.27 |
Prev. close | $3.08 | 52-week low | $1.54 |
Day low | $3.02 | Volume | 698,300 |
Day high | $3.24 | Avg. volume | 748,395 |
50-day MA | $3.38 | Dividend yield | N/A |
200-day MA | $2.63 | Market Cap | 307.80M |
PSTX Stock Price Chart Interactive Chart >
PSTX POWR Grades
- PSTX scores best on the Sentiment dimension, with a Sentiment rank ahead of 75.78% of US stocks.
- PSTX's strongest trending metric is Value; it's been moving down over the last 26 weeks.
- PSTX's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).
PSTX Stock Summary
- Of note is the ratio of POSEIDA THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 7.47% of US stocks have a lower such ratio.
- In terms of twelve month growth in earnings before interest and taxes, POSEIDA THERAPEUTICS INC is reporting a growth rate of 416.77%; that's higher than 97.17% of US stocks.
- As for revenue growth, note that PSTX's revenue has grown -67.2% over the past 12 months; that beats the revenue growth of merely 3.2% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to POSEIDA THERAPEUTICS INC are RPTX, RNA, ABUS, SYRS, and STTK.
- To dig deeper into the stock's financial statements, go to PSTX's page on browse-edgar?action=getcompany&CIK=0001661460.
PSTX Valuation Summary
- PSTX's EV/EBIT ratio is -3.1; this is 121.23% lower than that of the median Healthcare stock.
- Over the past 42 months, PSTX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for PSTX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
PSTX | 2023-12-29 | 6.5 | 2.6 | -2.4 | -3.1 |
PSTX | 2023-12-28 | 6.7 | 2.7 | -2.5 | -3.2 |
PSTX | 2023-12-27 | 6.5 | 2.6 | -2.5 | -3.1 |
PSTX | 2023-12-26 | 6.5 | 2.6 | -2.4 | -3.1 |
PSTX | 2023-12-22 | 6.5 | 2.6 | -2.4 | -3.1 |
PSTX | 2023-12-21 | 6.6 | 2.6 | -2.5 | -3.2 |
PSTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PSTX has a Quality Grade of C, ranking ahead of 26.69% of graded US stocks.
- PSTX's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows PSTX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0 | NA | -0.612 |
2021-03-31 | 0 | NA | -0.563 |
2020-12-31 | 0 | NA | -0.678 |
PSTX Price Target
For more insight on analysts targets of PSTX, see our PSTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $25.67 | Average Broker Recommendation | 1.12 (Strong Buy) |
Poseida Therapeutics Inc. (PSTX) Company Bio
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
Latest PSTX News From Around the Web
Below are the latest news stories about POSEIDA THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! |
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate. The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma |
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining HealthcareThe article embarks on a transformative journey through the biopharmaceutical frontier, where the listed companies stand as titans reshaping healthcare norms. |
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2023. |
Poseida Therapeutics to Present at Two Upcoming Investor ConferencesPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will participate in the following upcoming investor conferences in November: |
PSTX Price Returns
1-mo | -14.25% |
3-mo | -5.06% |
6-mo | 34.03% |
1-year | 2.24% |
3-year | -64.00% |
5-year | N/A |
YTD | -5.06% |
2023 | -36.60% |
2022 | -22.17% |
2021 | -37.92% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...